Development. Moreover, the Book Lays the Groundwork for Continued
Total Page:16
File Type:pdf, Size:1020Kb
Drawing on real-life examples, this book demonstrates the applications of transition metal catalysis in drug discovery and development, and its role in the efficient creation of both preclinical and clinical drug candidates as well as commercialized drugs. The authors pay particular attention to the challenges of transitioning reactions developed in academic labs into scalable industrial processes. Applications of Transition Metal Catalysis in Drug Discovery and Development begins with a general overview of the use of transition metal catalysis in the pharmaceutical industry. Next, it covers: • Transition metal-catalyzed carbon-carbon cross-coupling reactions • Palladium- and copper-catalyzed carbon-heteroatom cross-coupling reactions • Asymmetric cross-coupling reactions and metathesis • Transition metal-catalyzed synthesis of five- and six-membered heterocycles • Oxidative catalysis and industrial asymmetric hydrogenation Both the editors and authors are internationally recognized experts in drug discovery and development. All authors are scientists from such major pharmaceutical companies as Boehringer Ingelheim, GlaxoSmithKline, Merck, Amgen, and Novartis. Additionally, many of the authors have been responsible for developing the reactions and the drugs discussed in the book, providing readers with firsthand accounts of their discoveries. This remarkable work serves as a guide, historical perspective, and practical compendium, offering pharmaceutical researchers and medicinal chemists a unique perspective on the applications of transition metal catalysis in drug discovery and development. Moreover, the book lays the groundwork for continued development of transition metal-catalyzed processes, setting the stage for new and promising drug candidates. ABOUT THE AUTHORS EDITORS Professor Barry M. Trost Bom in Philadelphia, Pennsylvania in 1941 where he began his university training at the University of Pennsylvania (BA, 1962), he obtained a Ph.D. degree in Chemistry just three years later at the Massachusetts Institute of Technology (1965). He directly moved to the University of Wisconsin where he was promoted to Professor of Chemistry in 1969 and subsequently became the Vilas Research Professor in 1982. He joined the faculty at Stanford as Professor of Chemistry in 1987 and became Tamaki Professor of Humanities and Sciences in 1990. In addition, he has been Visiting Professor of Chemistry in Denmark (University of Copenhagen), France (Universities of Paris VI and Paris-Sud), Germany (Universities of Marburg, Hamburg and Munich), Italy (University of Pisa), Spain (Universities of Barcelona and Santiago de Compostela) and the UK (Cambridge University). In 1994 he was presented with a Docteur Honoris Causa of the Universite Claude-Bernard (Lyon I), France, and in 1997 a Doctor Scientiarum Honoris Causa of the Technion, Haifa, Israel. In 2006, he was appointed Honorary Professor of the Shanghai Institute of Organic Chemistry. Professor Trost's work has been characterized by a very high order of imagination, innovation and scholarship. He has ranged over the entire field of organic synthesis, particularly emphasizing extraordinarily novel methodology. Further, he has repeat¬ edly demonstrated how his innovative methodology allows for the simplification of many complex target oriented syntheses leading to natural products of high biolog¬ ical activity. Early in his career, Professor Trost participated in the isolation and structure determination of the Cecropia Juvenile hormone. These studies helped to xi xii ABOUT THE AUTHORS promulgate the concept that insect growth regulators can serve as ecologically preferable alternatives to pesticides. The long term goal and defining mission of Professor Trost's career has been toward enhancing synthetic effectiveness. He has virtually created whole new methodologies and strategies in organic synthesis. Among the areas which he has pioneered are the use of sulfur based reagents and transition metal, most notably palladium, and more recently ruthenium, catalysts in complex setting. More recently, his work has focused on enantioselective catalysts via the rational design of "chiral space." This work requires a detailed grasp of the mechanistic nuances of organometallic reactions. As part of this program, he designed a new class of ligands that spontaneously forms dinuclear complexes that are proving to be especially effective at asymmetric catalysis. Another con¬ tinuing theme, directed to the realities of organic synthesis in fostering commercial goals, is the strategy of "atom economy." Thus, synthetic building blocks are combined to produce complex targets in high yield with a bare minimum of debris under the guidance of carefully crafted catalysts. In this way, organic synthesis can be brought to bear in process settings to reach substances of high complexity in a commercially feasible way which minimizes environmental impact. Barry Trost's triumphs in total synthesis include complex terpenoids, steroids, alkaloids, vitamins, antibiotics, nucleosides and macrolides. His syntheses are conducted with charac¬ teristic flair and serve as learning resources in addressing the limits of the meth¬ odology which he tends to develop independently. In recognition of his many contributions, Professor Trost has received a number of awards, including the ACS Award in Pure Chemistry (1977), the ACS Award for Creative Work in Synthetic Organic Chemistry (1981), the Baekeland Award (1981), the first Allan R. Day Award of the Philadelphia Organic Chemists' Club (1983), the Chemical Pioneer Award of the American Institute of Chemists (1983), the Alex¬ ander von Humboldt Stiftung Award (1984), MERIT Award of NIH (1988), Hamilton Award (1988), Arthur C. Cope Scholar Award (1989), Guenther Award in the Chemistry of Essential Oils and Related Products (1990), the Dr. Paul Janssen Prize (1990), the ASSU Graduate Teaching Award (1991), Pfizer Senior Faculty Award (1992), Bing Teaching Award (1993), the ACS Roger Adams Award (1995), the Presidential Green Chemistry Challenge Award (1998), the Herbert C. Brown Award for Creative Research in Synthetic Methods (1999), the Belgian Organic Synthesis Symposium Elsevier Award (2000), the Nichols Medal (2000), the Yamada Prize (2001), the ACS Nobel Laureate Signature Award for Graduate Education in Chemistry (2002), the ACS Cope Award (2004), the City of Philadelphia John Scott Award (2004), Thomson Scientific Laureate (2007), the Kitasato Microbial Chem¬ istry Medal, and the Nagoya Medal (2008). He has held a Sloan Fellowship, a Camille and Henry Dreyfus Teacher-Scholar grant and an American-Swiss Foundation Fellowship as well as having been the Julius Stieglitz Memorial Lecturer of the ACS-Chicago section (1980-81) and Centenary Lecturer of the Royal Society of Chemistry (1981-82). Professor Trost has been elected a Fellow of the American Academy of Sciences (1982) and a member of the National Academy of Sciences He has served (1980). as editor and on the editorial board of many books and journals, including being Associate Editor of the Journal of the American Chemical Society ABOUT THE AUTHORS xiii (1974-80). He has served as a member of many panels and scientific delegations, and served as Chairman of the NIH Medicinal Chemistry Study Section. He has held over 120 special university lectureships and presented over 260 Plenary Lectures at national and international meetings. He has published two books and over 840 scientific articles. He edited a major compendium entitled Comprehensive Organic Synthesis consisting of nine volumes and serves as editor for ChemTracts/Organic Chemistry. Dr. Matthew L. Crawley Matthew Lantz Crawley obtained his B.A. degree from Williams College with a double major in political economy and chemistry under the guidance of Professor J. Hodge Markgraf. In 1998, he started his graduate studies with Professor Barry M. Trost at Stanford University, where his work focused on the development of asymmetric palladium-catalyzed reactions with applications in total synthesis. After completion of his Ph.D., Matthew joined the medicinal chemistry department of Incyte Corporation in Delaware, where he worked for several years. From late 2005 through 2010, Matthew worked at Wyeth Research in Pennsylvania (now Pfizer), first as a Senior Research Scientist and then as a Team Leader and Principal Research Scientist doing drug discovery in an array of therapeutic areas, including neuroscience, inflammation, and cardiovascular and metabolic disease. Most recently, while remaining active in chemistry through consulting, his work has focused on the healthcare sector where he is the Director of Electronic Medical Records for the Philadelphia based Main Line Health system. Matthew has authored or coauthored dozens of publications and is an inventor on several non-provisional and issued patents. AUTHORS Dr. Chris H. Senanayake Dr. Chris H. Senanayake was born in Sri Lanka and received a BS degree (First Class) in Sri Lanka. After coming to the United States, he completed his MS at Bowling Green State University with Professor Thomas Kinstle in synthetic chemistry. He obtained his Ph.D. under the guidance of Professor James H. Rigby at Wayne State University in 1987 where he worked on the total synthesis of complex natural products such as, ophiobolanes, and completed the first total synthesis of grosshemin in the guaianolide family. He then undertook a postdoctoral fellow with Professor Carl R. Johnson and worked on the total synthesis of polyol systems such